{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:56:01Z","timestamp":1789016161959,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chimeric Antigen Receptor T-cell (CAR T) therapy has become the preferable treatment in relapsed\/refractory diffuse large B-cell lymphomas (DLBCL) patients. Detection of CAR Ts in peripheral blood smear (PBS) is challenging due to insufficient data regarding their morphology and low sensitivity. The morphological evolution of CAR Ts along their production process, and in patients, was established by Full-Field Morphology (FFM), a novel digital microscopy approach that provides highly sensitive PBS analysis. At day 8 of production, 42.7 \u00b1 10.8% of the CAR T transduced cells exhibited activated morphology compared with 9.3 \u00b1 3.8% in untransduced cells. Moreover, engagement of transduced CAR Ts with target cells resulted in further morphological transformation into activated morphology (83 \u00b1 5.6% of the cells). In patients, the average number of day 5 CAR Ts, and their sustained presence, were significantly higher in patients obtaining complete response. A high number of activated morphology CAR Ts at day 14 was associated with prolonged cytokine release storm. Overall, CAR Ts exhibited heterogeneous morphology, with the activated morphology attributed predominantly to transduced cells following engagement with target cells. Post-transfusion CAR T detection was associated with increased complete responses. FFM CAR T surveillance in PBS may serve as a simple inexpensive method to provide clinically relevant insights into this treatment modality.<\/jats:p>","DOI":"10.3390\/cancers15235611","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T07:40:01Z","timestamp":1701157201000},"page":"5611","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Clinical Significance of Circulating Lymphocytes Morphology in Diffuse Large B-Cell Lymphoma As Determined by a Novel, Highly Sensitive Microscopy"],"prefix":"10.3390","volume":"15","author":[{"given":"Gil","family":"Fridberg","sequence":"first","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Horn","sequence":"additional","affiliation":[{"name":"Immunology and Advanced CAR-T Therapy Laboratory, Tel Aviv Sourasky Medical Center, Dotan Center for Advanced Therapies, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7557-463X","authenticated-orcid":false,"given":"Anat","family":"Globerson Levin","sequence":"additional","affiliation":[{"name":"Immunology and Advanced CAR-T Therapy Laboratory, Tel Aviv Sourasky Medical Center, Dotan Center for Advanced Therapies, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Benisty","sequence":"additional","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigi","family":"Kay","sequence":"additional","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Glait-Santar","sequence":"additional","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chava","family":"Perry","sequence":"additional","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-6930","authenticated-orcid":false,"given":"Ron","family":"Ram","sequence":"additional","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5058-943X","authenticated-orcid":false,"given":"Ben-Zion","family":"Katz","sequence":"additional","affiliation":[{"name":"The Hematology Division, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Eng. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Eng. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_4","unstructured":"FDA (2022, June 05). KYMRIAH (Tisagenlecleucel), Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"key":"ref_5","unstructured":"FDA (2022, June 05). YESCARTA (Axicabtagene Ciloleucel), Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Eng. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1182\/blood-2021-150721","article-title":"A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry","volume":"138","author":"Bachy","year":"2021","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood-2018-99-115252","article-title":"Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel","volume":"132","author":"Schuster","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The Emerging Landscape of Immune Cell Therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv."},{"key":"ref_14","first-page":"535","article-title":"Monitoring of tisagenlecleucel transgene DNA using a quantitative polymerase chain reaction assay","volume":"20","author":"Davis","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/ijlh.13106","article-title":"Useful prognostic tools based on complete blood cell counts in diffuse large B-cell lymphoma","volume":"41","author":"Shimono","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","article-title":"Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse","volume":"5","author":"Faude","year":"2021","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.14286","article-title":"The cytological features of CAR (T) cells","volume":"175","author":"Brooks","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ijlh.13681","article-title":"Evaluation of Scopio Labs X100 Full Field PBS: The first high-resolution full field viewing of peripheral blood specimens combined with artificial intelligence-based morphological analysis","volume":"43","author":"Katz","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1158\/2326-6066.CIR-20-0118","article-title":"Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual SpecificityMM Treatment with dCAR138-38\u2013Redirected T Cells","volume":"8","author":"Waks","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0022-1759(00)00343-4","article-title":"Functional expression of chimeric receptor genes in human T cells","volume":"248","author":"Eshhar","year":"2001","journal-title":"J. Immunol. Meth."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: Interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cyto.b.21880","article-title":"New directions in chimeric antigen receptor T cell [CAR-T] therapy and related flow cytometry","volume":"98","author":"Maryamchik","year":"2020","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e006596","DOI":"10.1136\/jitc-2022-006596","article-title":"CAR T-cell detection scoping review: An essential biomarker in critical need of standardization","volume":"11","author":"Turicek","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1532\/LH96.05019","article-title":"The international consensus group for hematology review: Suggested criteria for action following automated CBC and WBC differential analysis","volume":"11","author":"Barnes","year":"2005","journal-title":"Lab. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Benmebarek, M.R., Karches, C.H., Cadilha, B.L., Lesch, S., Endres, S., and Kobold, S. (2019). Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061283"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2020","journal-title":"Oncogene"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory PhenotypeSuperior Antitumor Activity of CAR-T Cells Cultured in IL15","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Eng. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Eng. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Eng. J. Med."},{"key":"ref_36","unstructured":"(2022, April 28). EBMT 2022\u2014Program. Available online: https:\/\/ebmt2022.abstractserver.com\/program\/#\/details\/presentations\/1153."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5611\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:32:00Z","timestamp":1760131920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":36,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15235611"],"URL":"https:\/\/doi.org\/10.3390\/cancers15235611","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}